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Abstract
Background: Although the etiology of primary biliary cirrhosis (PBC) remains enigmatic, there are several pieces of
data supporting the thesis that a strong genetic predisposition and environmental factors interact to produce a
selective loss of tolerance. The striking female predominance of PBC has suggested that this sex predisposition may
be secondary to epigenetic alterations on the X chromosome. In the present study, we rigorously defined the X
chromosome methylation profile of CD4, CD8, and CD14 cells from 30 PBC patients and 30 controls. Genomic DNA
from sorted CD4, CD8, and CD14 subpopulations was isolated, sonicated, and immunoprecipitated for analysis of
methylation. All products were hybridized to a custom-tiled four-plex array containing 27,728 CpG islands annotated
by UCSC and 22,532 well-characterized RefSeq promoter regions. Furthermore, bisulfite sequencing was then used
for validation on a subsequent group of independent samples from PBC patients and controls. Thence, expression
levels of selected X-linked genes were evaluated by quantitative real-time PCR with cDNA samples from all subjects.
Results: We report herein that a total of 20, 15, and 19 distinct gene promoters reflected a significant difference in
DNA methylation in CD4+ T, CD8+ T, and CD14+ cells in patients with PBC. Interestingly, there was hypermethylation
of FUNDC2 in CD8+ T cells and a striking demethylation of CXCR3 in CD4+ T cells, which inversely correlated with
CXCR3 expression levels in CD4+ T cells from early-stage PBC patients.
Conclusions: Our data provides a set of genes with epigenetic alteration likely to be indicators of autoimmunity and
emphasizes the role of CXCR3 in the natural history of PBC.
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Background
Autoimmune diseases are multifactorial in origin. Gen-
etic background confers susceptibility to disease onset
but is not sufficient for disease development. Epigenetic
mechanisms such as DNA methylation and histone
modifications regulate gene expression levels and provide
an alternative mechanism for modulating gene function
and genetic changes. Importantly, DNA methylation plays
an important role in T cell differentiation [1, 2], and the
potential role of epigenetics in environment and genetics
interaction has been widely suggested in autoimmunity
[3, 4]. With these data in mind, we note that primary
biliary cirrhosis (PBC) is characterized by the presence
of high titers of circulating antimitochondrial antibodies
(AMAs), innate immune system activation [5–7], and
liver-infiltrating autoreactive CD4 and CD8 T lympho-
cytes [8–10], leading to the progressive destruction of
small intrahepatic bile ducts [11, 12]. Genetic polymor-
phisms account for individual susceptibility to PBC in a
minority of cases, as supported by genome-wide associ-
ation (GWAS) data [13–17], while environmental factors
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may act through epigenetic changes, as demonstrated for
specific genes [18–20]. It has long been known that there
is a striking female sex bias in PBC [21], and recent data
has suggested involvement of sex chromosomes [22, 23].
For example, an enhanced X monosomy rate in peripheral
lymphocytes has been demonstrated in women with PBC
[24], despite random X chromosome inactivation [25], as
well as an increased Y loss in men with PBC [26].
We thus hypothesized that there is an X chromosome
epigenetic component in PBC. Herein we performed an
extensive X chromosome methylation analysis in CD4,
CD8, and CD14 cells from PBC patients and controls,
coupled with gene expression profile from the same cells.
The frequency of CXCR3-expressing cells in peripheral
blood is known to be higher in PBC patients, and CXCR3-
positive cells are found in the portal areas of diseased livers,
primarily on CD4+ T cells [27]. Moreover, we report that
the CXCR3 promoter is demethylated in CD4+ Tcells from
PBC patients and the expression level of CXCR3 in CD4+
T cells is significantly increased in comparison to controls
and inversely correlated with the overall methylation levels
of the CXCR3 promoter, indicating that promoter demeth-
ylation status contributed to CXCR3 overexpression in
CD4+ T cells. Hence, we submit that there is an epigenetic
mechanism that underlies CXCR3 expression in PBC. Our
findings not only identify potentially relevant DNA methy-
lation markers for the clinical characterization of PBC pa-
tients but also support the thesis that epigenetic changes
may be critical for the clinical manifestations of PBC.
Results
DNA methylation
Initially, X chromosome methylated DNA immunoprecip-
itation (MeDIP) arrays were performed on cell subsets
from 10 PBC patients and 10 controls (Fig. 1). We identi-
fied 8 hypomethylated genes and 12 hypermethylated
genes in CD4+ cells, 3 hypomethylated genes and 12
hypermethylated genes in CD8+ cells, and 9 hypomethy-
lated genes and 10 hypermethylated genes in CD14+ cells
in PBC compared with normal controls (Fig. 2, Table 1).
Gene ontology (GO) analysis was conducted to identify
the cell component, molecular function, and biological
processes of these genes. Bisulfite sequencing was thence
used to validate the results of the MeDIP-ChIP. Based on
the GO analysis, four genes were chosen for validation in
CD4+, CD8+, and CD14+ cells from 20 additional PBC
patients and 20 additional normal controls. Importantly,
CXCR3 was demonstrated to be significantly hypomethy-
lated in CD4+ T cells from PBC patients (Fig. 3), whereas
UBE2A and FUNDC2 were hypermethylated in CD4+ T
cells and CD8+ T cells, respectively, in PBC patients
(Figs. 4 and 5). IL1RAPL2 was hypermethylated in CD14+
cells in PBC (Fig. 6).
Gene expression
CXCR3, UBE2A, FUNDC2, and IL1RAPL2 expression
was studied by reverse transcription and quantitative
polymerase chain reaction (RT-qPCR) in CD4+, CD8+,
and CD14+ cells in a cohort of 30 PBC and 30 normal
controls (Fig. 7).
Importantly, CXCR3 was significantly overexpressed in
CD4+ T cells in PBC (p = 0.0055), whereas FUNDC2
was significantly less expressed in CD8+ T cells from
PBC than controls (p = 0.0134). These results are con-
cordant with the methylation data. IL1RAPL2 was not
expressed in any cell subset in PBC or controls, and no
significant differences were identified for UBE2A in the
three subsets investigated (data not shown). Finally, a
Fig. 1 Flow chart illustrating the study design
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Fig. 2 (See legend on next page.)
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significant negative correlation between CXCR3 expres-
sion and overall methylation levels in CD4+ T cells was
found in early-stage PBC patients (p < 0.05) (Fig. 8a). Of
note, there was no difference observed based on UDCA
treatment (data not shown). In addition, our data demon-
strated that CXCR3 expression levels in CD4+ T cells were
significantly associated with duration of disease (p < 0.01)
(Fig. 8b) but not associated with age (data not shown).
CD4 T cell phenotype
Finally, we quantified CD4 T cell populations expressing
CXCR3 in both PBC (n = 20) and controls (n = 10) by
flow cytometry. Based on the expression data, patients
with PBC had an increased number in the periphery of
CD4 T cells expressing CXCR3. In addition, both naïve
and memory CD4 T cells from PBC expressed a higher
frequency of CXCR3 cells in the periphery than controls.
However, only activated CD4+CD45RO+ cells expressed
significantly higher levels of CXCR3 (41.82 % ± 4.37 ver-
sus 27.57 % ± 2.61, p = 0.0094) (Fig. 9). Please note we
included both early (n = 10) and advanced (n = 10) stage
patients with PBC (data not shown).
Discussion
As the case for most autoimmune diseases, PBC results
from the contribution of genetic and environmental fac-
tors, reflected by incomplete concordance in monozygotic
twins [28]. Moreover, our group has suggested a signifi-
cant role for X chromosome defects in PBC, based on the
observation that women with PBC have a significantly en-
hanced monosomy X frequency in peripheral white blood
cells compared to age- and disease stage-matched women
with chronic viral hepatitis and to age-matched healthy
women [24]. Epigenetic mechanisms act at the interface of
genetic and environmental influences on human pheno-
type and disease risk by altering gene expression levels
without altering DNA sequence or chromosome structure.
In the case of autoimmune diseases, epigenetic mecha-
nisms have been implicated in the pathogenesis of sys-
temic lupus erythematosus [29, 30] and type I diabetes
[31]. Moreover, we had previously explored the X chromo-
some epigenetic component in PBC [18].
Importantly, PBC is a complex autoimmune disease
involving autoreactive CD4+ and CD8+ T cell responses,
present in human circulating lymphocytes and liver, B
cell compartment, and innate immunity, including mac-
rophages [6, 32–34].
In this study, we investigated for the first time the
DNA methylation status of the X chromosome in CD4+,
CD8+, and CD14+ cells isolated from PBC patients and
well-matched controls. We herein demonstrate that the
CXCR3 promoter is demethylated in CD4+ T cells from
PBC patients compared to controls, which is supported
by a significantly higher expression of CXCR3 in the
same cell subtype of PBC patients. CXCR3 gene encodes
a G protein-coupled receptor with selectivity for three
chemokines: CXCL9 or MIG (monokine induced by
IFNγ), CXCL10 or IP10 (IFNγ-inducible 10 kDa pro-
tein), and CXCL11 or I-TAC (IFN-inducible T cell α-
chemoattractant). CXCR3 plays an important role in
regulating leukocyte trafficking; indeed binding of che-
mokines induces cellular responses that are involved in
leukocyte traffic, most notably integrin activation, cyto-
skeletal changes, and chemotactic migration. CXCR3 is
expressed primarily on activated T lymphocytes and NK
cells and some epithelial cells and endothelial cells. It
had been implicated that CXCR3 is highly expressed on
pro-inflammatory human CD4+Th17 cells [35], “patho-
genic” human Th1/17 cells [36], and myelin oligodendro-
cyte glycoprotein-specific CD4+ T cells in experimental
autoimmune encephalomyelitis mice in combination with
other biomarkers [37]. Increased CXCR3 in portal tracts
has also been reported in PBC patients [27]. Additionally,
levels of CXCR3 ligands are markedly increased in inflam-
matory liver diseases [38, 39], including PBC [27]. Further,
knockout of CXCR3 delays PBC progression in an animal
model [40]. Most importantly, our data indicates that
CXCR3 expression in CD4+ T cells inversely correlates
with methylation levels and positively correlates with
duration of disease. The accumulated data suggest a
critical role of the CXCR3/chemokine system in the de-
velopment of autoimmune disorders. In addition to its
role in lymphocyte recruitment to tissues, CXCR3 is
also implicated in the development of Th1 cells within
lymph nodes [41]; thus, hypomethylation of CXCR3
and the consequent increased expression on CD4 T
cells could promote disease progression through en-
hanced Th1 differentiation and increased recruitment.
X chromosome demethylation has been shown to result
in increased CXCR3 expression in lupus, suggesting
this could be a common mechanism that contributes to
the female susceptibility to autoimmune diseases [4].
Our findings are in agreement with previous studies;
nevertheless, our findings strongly suggest an epigenetic
(See figure on previous page.)
Fig. 2 Differential methylation between PBC-affected subjects (n = 10) and healthy controls (n = 10) in CD4+, CD8+, and CD14+ cells represented
in a heat map. The genomic locations of genes are shown on the left of the X chromosome ideogram. On the right, different methylated regions
(DMR) of genes are identified in at least 6/10 samples in one group and 3/10 samples in the other. The predicted DMR along with the names of
the genes in each cell examined is depicted as a two-dimensional heat map, respectively. Black blocks represent zero peaks, and yellow blocks
symbolize different peak numbers corresponding to the scale bar at the bottom
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Table 1 Differentially methylated genes between PBC patients (n = 10) and controls (n = 10) in CD4+ T cells, CD8+ T cells, and CD14+ cells from MeDIP array
Gene symbol Promoter methylation Chromosome location Peak start Peak end Molecular function
CD4+ T cells
SHROOM2 Hypo Xp22.3 9712072 9712217 Protein binding; actin binding; ion channel activity
ATP6AP2 Hypo Xp11.4 40325091 40325230 Receptor activity; protein binding; peptidase activity
CXCR3 Hypo Xq13 70754908 70755379 Protein binding; receptor activity
KIAA1210 Hypo Xq24 118168783 118168934 –
RAP2C Hypo Xq25 131181458 131182027 Nucleotide binding; hydrolase activity
HTATSF1 Hypo Xq26.3 135407214 135407962 RNA binding; nucleotide binding
SRPK3 Hypo Xq28 152699372 152700237 Protein binding; nucleotide binding; protein kinase activity
IDH3G Hypo Xq28 152712248 152713105 Nucleotide binding; catalytic activity; binding
SH3KBP1 Hyper Xp22.1-p21.3 19815048 19815499 Kinase activity; protein binding
PHEX Hyper Xp22.2-p22.1 21960765 21961408 Binding; peptidase activity
USP9X Hyper Xp11.4 40829716 40830189 –
EBP Hyper Xp11.23-p11.22 48265283 48265716 –
PQBP1 Hyper Xp11.23 48638698 48639426 DNA binding; protein binding; transcription regulator activity
KDM5C Hyper Xp11.22-p11.21 53270826 53271657 Catalytic activity; binding; DNA binding; transferase activity
IL13RA1 Hyper Xq24 117745388 117746245 Protein binding; receptor activity
UBE2A Hyper Xq24 118592639 118593104 Catalytic activity; protein binding; nucleotide binding
CUL4B Hyper Xq23 119578240 119579025 Protein binding
DCAF12L1 Hyper Xq25 125513992 125514963 –
GPC4 Hyper Xq26.1 132376771 132377010 Protein binding
FAM50A Hyper Xq28 153325585 153326034 –
CD8+ T cells
MAGEB2 Hypo Xp21.3 30142775 30143514 –
PIN4 Hypo Xq13 71318699 71318834 DNA binding; catalytic activity
IDH3G Hypo Xq28 152713172 152713419 Nucleotide binding; catalytic activity; binding
GPR143 Hyper Xp22.3 9693469 9693810 Binding; protein binding
CHST7 Hyper Xp11.23 46317790 46318126 Transferase activity
NDUFB11 Hyper Xp11.23 46889596 46889747 –
RBM10 Hyper Xp11.23 46889596 46889747 RNA binding; nucleotide binding
ZXDB Hyper Xp11.21 57635489 57636052 Nucleic acid binding; binding; protein binding; sequence-specific
DNA binding transcription factor activity
DOCK11 Hyper Xq24 117514077 117514418 Enzyme regulator activity; lipid binding; protein binding
IL13RA1 Hyper Xq24 117745582 117746125 Protein binding; receptor activity
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Table 1 Differentially methylated genes between PBC patients (n = 10) and controls (n = 10) in CD4+ T cells, CD8+ T cells, and CD14+ cells from MeDIP array (Continued)
RNF113A Hyper Xq24 118889675 118890227 Binding; protein binding
AIFM1 Hyper Xq26.1 129101688 129102158 Catalytic activity; nucleotide binding; protein binding; electron
carrier activity; DNA binding
MPP1 Hyper Xq28 153686370 153686806 Kinase activity; protein binding
FUNDC2 Hyper Xq28 153908428 153908659 –
RAB39B Hyper Xq28 154146437 154146790 Nucleotide binding
CD14+ cells
SYAP1 Hypo Xp22.2 16647938 16648203 –
DYNLT3 Hypo Xp21 37591227 37591696 –
CASK Hypo Xp11.4 41667126 41667877 Protein binding; ATP binding; protein kinase activity
GPR173 Hypo Xp11 53095323 53095568 G protein-coupled receptor activity
CITED1 Hypo Xq13.1 71441965 71442118 Sequence-specific DNA binding transcription factor activity;
protein binding; DNA binding; transcription regulator activity;
chromatin binding; hydrolase activity
GPRASP1 Hypo Xq22.1 101790525 101790970 Protein binding
RNF128 Hypo Xq22.3 105824083 105824257 Binding; catalytic activity
NSDHL Hypo Xq28 151750127 151750280 Catalytic activity
SSR4 Hypo Xq28 152710848 152711207 Calcium ion binding
KAL1 Hyper Xp22.32 8659278 8659655 Enzyme regulator activity; protein binding; carbohydrate binding;
structural molecule activity
SH3KBP1 Hyper Xp22.1-p21.3 19815148 19815397 Protein binding
USP11 Hyper Xp11.23 46976944 46977091 Peptidase activity; protein binding; hydrolase activity
PIM2 Hyper Xp11.23 48661207 48661380 Protein kinase activity; nucleotide binding
PCDH11X Hyper Xq21.3 90921374 90921541 Calcium ion binding
IL1RAPL2 Hyper Xq22 103696629 103696884 Protein binding; receptor activity
PSMD10 Hyper Xq22.3 107221347 107221874 Protein binding
ATG4A Hyper Xq22.1-q22.3 107221347 107221874 Peptidase activity
DCAF12L1 Hyper Xq25 125513614 125513941 Protein binding
FUNDC2 Hyper Xq28 153908232 153908879 –
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Fig. 3 Bisulfite sequencing-based DNA methylation analysis of the CXCR3 promoter region in CD4+ T cells. a Chromosomal sequence location of
the CXCR3 promoter that was analyzed by bisulfite sequencing. This region contains four CpG sites (vertical bars) within a 471 bp region overlapping
the transcription start site as shown. b Representative bisulfite sequencing data from CD4+ cells of a PBC sample and a normal control, respectively.
Each circle represents a CpG site, and each line represents an individually sequenced clone. Filled circles represent methylated sites (protected from
bisulfite conversion), while unfilled circles represent unmethylated CpG sites (converted). c Mean methylation level was calculated for each individual
CpG site within the CXCR3 promoter region for all clones for PBC (n = 20) versus healthy (n = 20) CD4+ cells. d Overall percentage of methylation of
CXCR3 was determined by the total number of methylated sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (n = 20)
versus healthy (n = 20) CD4+ cells. **p < 0.01
Fig. 4 a Chromosomal sequence location of the region of the UBE2A promoter that was analyzed by bisulfite sequencing. This region contains
20 CpG sites (vertical bars) within a 542 bp region upstream of the transcription start site as shown. b Representative bisulfite sequencing data
from CD4+ cells of a PBC sample and a normal control, respectively. Each circle represents a CpG site, and each line represents an individually
sequenced clone. Filled circles represent methylated sites (protected from bisulfite conversion), while unfilled circles represent unmethylated CpG
sites (converted). c Mean methylation level was calculated for each individual CpG site within the UBE2A promoter region for all clones for PBC
(n = 20) versus healthy (n = 20) CD4+ cells. d Overall percentage of methylation of UBE2A was determined by the total number of methylated
sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (n = 20) versus healthy (n = 20) CD4+ cells. *p < 0.05
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mechanism underlying the elevated CXCR3 expression
in PBC.
There are significant limitations in our study that should
be discussed. First, of the genes studied herein, we note
there were no significant differences identified for UBE2A
gene expression, although UBE2A has been demonstrated
to be hypermethylated in CD4+ T cells. This suggests that
UBE2A expression is regulated by other epigenetic mech-
anisms rather than by methylation. Second, the patho-
genetic mechanisms that underlie CXCR3 demethylation
remain to be defined. Third, our study did not include
men with PBC. This is of particular interest given the rele-
vant function of the X chromosome. Fourth, the CD4 bias
is interesting and it will be important to determine if this
bias is found on other T cell subpopulations, particularly
Th17, Tregs, or Th1 cells, all of which require CXCR3 to
enter the liver. Finally, further studies will also need to
focus on the differential expression of central versus ef-
fector memory cells. Our data highlight, however, the
critical importance of epigenetics in PBC and likely for
other autoimmune diseases.
Conclusions
CXCR3 promoter demethylation in CD4+ T cells from
PBC patients, supported by a significantly higher expression
of CXCR3 in the same cell subtype, emphasizes the
well-known role of CXCR3 in the pathogenesis of PBC.
Moreover, CXCR3 expression levels in CD4+ T cells are
significantly associated with duration of disease. Whether
CXCR3 may contribute to the female susceptibility to
PBC warrants further investigation.
Methods
Subjects
Fresh heparinized peripheral blood samples were obtained
from 30 patients diagnosed with PBC and 30 unaffected
age- and sex-matched controls [11]. All patients (Table 2)
were female, and 90 % had readily detectable AMA; the
Fig. 5 a Chromosomal sequence location of the region of the FUNDC2 promoter that was analyzed by bisulfite sequencing. This region contains
80 CpG sites (vertical bars) within a 696 bp region close to the transcription start site as shown. b Representative bisulfite sequencing data from
CD8+ cells of a PBC sample and a normal control, respectively. Each circle represents a CpG site, and each line represents an individually sequenced
clone. Filled circles represent methylated sites (protected from bisulfite conversion), while unfilled circles represent unmethylated CpG sites (converted).
c Mean methylation level was calculated for each individual CpG site within the FUNDC2 promoter region for all clones for PBC (n = 20) versus healthy
(n = 20) CD8+ cells. d Overall percentage of methylation of FUNDC2 was determined by the total number of methylated sites out of the total CpG
sites in all clones and graphed as mean ± SD for PBC (n = 20) versus healthy (n = 20) CD8+ cells. *p < 0.05
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diagnosis was made based on internationally accepted cri-
teria [11]. The mean age was 61 (43–78) years old (range
years), and 100 % of them were taking ursodiol. Four per-
cent of the PBC patients included in this study were histo-
logically characterized as cirrhotics. Serum liver function
tests were performed utilizing routine laboratory methods.
Subjects were excluded from the study if they had malig-
nancies or were using immunosuppressive drugs. Patients
and controls were matched for age and sex. After approval
from appropriate institutional review board, all subjects
provided written informed consent prior to enrollment in
the study. The study design is illustrated in Fig. 1.
CD14+, CD4+ T cell, and CD8+ T cell purification
Peripheral blood mononuclear cells (PBMC) were iso-
lated by centrifugation on a Ficoll-Hypaque gradient for
30 min at 500g. First, CD14+ cells were isolated from
PBMC by positive selection under endotoxin-free condi-
tions using anti-CD14 conjugated microbeads (Miltenyi
Biotec, San Diego, CA, USA). Thence, CD8+ cells were
isolated from the eluate by positive selection using anti-
CD8 conjugated microbeads (Miltenyi Biotec, San Diego,
CA, USA). Finally, the CD4+ T cells were isolated by
negative selection using a cocktail of antibodies against
CD8, CD14, CD16, CD19, CD36, CD56, CD123, TCR γ/
δ, and CD235a (Miltenyi Biotec, San Diego, CA, USA).
Aliquots of the CD14+, CD8+, and CD4+ T cells were
subjected to viability assays and flow cytometry analysis.
The purity of these lymphocytic populations was >95 %
and the viability >95 %. Genomic DNA from the isolated
CD14+, CD8+, and CD4+ T cells was isolated using TRI
Reagent (Sigma-Aldrich, St. Louis, MO, USA) [42].
Methylated DNA immunoprecipitation and methylation
microarrays
DNA samples from PBC patients (n = 10) and controls
(n = 10) were sonicated to generate fragments between
200 and 1000 base pairs (bp), and then immunoprecipi-
tated with a murine monoclonal antibody that specifically
recognizes 5-methylcytidine (Diagenode, Liège, Belgium).
The immunoprecipitated DNA fragments were recovered
using anti-mouse IgG magnetic beads. The MeDIP-
enriched DNA was amplified by PCR using universal
primers and a limited number of cycles (GenomePlex®
Fig. 6 a Chromosomal sequence location of the region of the IL1RAPL2 promoter that was analyzed by bisulfite sequencing. This region contains
23 CpG sites (vertical bars) within a 423 bp region upstream of the transcription start site as shown. b Representative bisulfite sequencing data
from CD14+ cells of a PBC sample and a normal control, respectively. Each circle represents a CpG site, and each line represents an individually
sequenced clone. Filled circles represent methylated sites (protected from bisulfite conversion), while unfilled circles represent unmethylated CpG
sites (converted). c Mean methylation level was calculated for each individual CpG site within the IL1RAPL2 promoter region for all clones for PBC
(n = 20) versus healthy (n = 20) CD14+ cells. d Overall percentage of methylation of IL1RAPL2 was determined by the total number of methylated
sites out of the total CpG sites in all clones and graphed as mean ± SD for PBC (n = 20) versus healthy (n = 20) CD14+ cells. **p < 0.01
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Complete Whole Genome Amplification kit). The amplified
DNA samples were then purified with QIAquick PCR puri-
fication kit (Qiagen, Valencia, CA, USA). One microgram
of immunoprecipitated and reference DNA was tagged
respectively with Cyanine-5 (Cy5) and Cyanine-3 (Cy3)
labeled random 9-mers and then hybridized by the
NimbleGen Array Hybridization Kit (Roche NimbleGen,
Madison, WI, USA). The labeled DNA was then puri-
fied by isopropanol/ethanol precipitation. For array
hybridization, Roche NimbleGen’s Human Promoter
plus CpG Island array was used, a 3 × 720k format array
design containing 27,728 CpG islands and all well-
characterized promoter regions (from about −2440
to +610 bp of the TSSs) totally covered by ~720,000
probes.
Bisulfite sequencing
The CpG island DNA methylation status was determined
by sequencing bisulfite-modified genomic DNA [43] from
PBC patients (n = 20) and controls (n = 20). One micro-
gram of genomic DNA was bisulfite-converted using the
EpiTect Bisulfite Kit (Qiagen, Valencia, CA, USA). For
Fig. 7 CXCR3 (a), and FUNDC2 (b) expression level was determined in CD4+, CD8+ T cells, and CD14+ cells in PBC patients and controls.
Real-time threshold cycle values for cDNA were normalized with GADPH and compared to a calibrator. Limits (95 % CI) of the best-fit line
are shown
Fig. 8 Correlation analysis was performed to evaluate the relationship between CXCR3 gene expression levels, methylation status of CXCR3
promoter, and disease duration. a CXCR3 expression in CD4+ T cells inversely correlates with methylation status of CXCR3 promoter. b CXCR3
expression in CD4+ T cells correlates with disease duration. Real-time threshold cycle values for CXCR3 cDNA were normalized with GADPH and
compared to a calibrator. Calibrated CXCR3 expression levels were correlated to disease duration (months). 95 % confidence limits of the best-fit
line are shown (solid line)
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each gene, primers were designed using the Methyl Primer
Express v1.0 program (Life Technologies-Applied Biosys-
tems, Carlsbad, CA, USA) corresponding to the region
containing the oligonucleotide probe represented in the
DNA methylation bead array. Ten positive recombinant
clones were selected randomly and sequenced using ABI
3730 (Life Technologies-Applied Biosystems, Carlsbad,
CA, USA). The methylation level of gene is assessed ac-
cording to the percentage of the methylated CG sites in
10 clones. All primer sequences are listed in Additional
file 1: Table S1.
Reverse transcription and quantitative polymerase chain
reaction
Total RNA was extracted from all isolated samples (PBC
n = 30, controls n = 30) using TRI Reagent (Sigma-Aldrich,
St. Louis, MO, USA). cDNA was synthesized from all dif-
ferent cell types using High Capacity cDNA Reverse Tran-
scription Kits (Life Technologies-Applied Biosystems,
Carlsbad, CA, USA). One hundred nanograms of cDNA
in a total volume of 20 μl was amplified for 40 cycles on
an Applied Biosystems 7900 HT Sequence Detection
System, using a TaqMan Gene Expression Assay spe-
cific for CXCR3, UBE2A, FUNDC2, and IL1RAPL2
(Cat. #4331182, #4351372, Life Technologies-Applied
Biosystems, Carlsbad, CA, USA). TaqMan® Gene Ex-
pression Assays consist of a pair of unlabeled PCR
primers and a TaqMan® probe with a FAM™ dye label
on the 5′ end and minor groove binder (MGB) nonflu-
orescent quencher (NFQ) on the 3′ end. RNA from
samples of interest is reverse transcribed into cDNA,
and the synthesized cDNA serves as the template for
real-time PCR. ROX™ dye is used as a passive reference
to normalize real-time PCR reactions. ROX™ dye pro-
vides an internal reference to which the FAM™ reporter
dye signal can be normalized, which is necessary to cor-
rect for fluorescent fluctuations due to changes in concen-
tration, volume, or light source intensity. Normalization of
the reporter dye signal results in increased data precision.
Fig. 9 CD4 T cell populations expressing CXCR3 in PBC (n = 20) and controls (n = 10) were quantified by flow cytometry. In PBC, there is an
increased number of CD4 T cells in the periphery expressing CXCR3, in both naïve (CD45RA) and memory cells (CD45RO). Activated CD4+CD45RO+
cells express significantly higher levels of CXCR3 in PBC (41.82 % ± 4.37) compared to controls (27.57 % ± 2.61) (p = 0.0094)
Table 2 Clinical, biochemical, and serological characteristics of
PBC patients
PBC patients Healthy controls
(n = 30) (n = 30)
Mean age (years, range) 64 (44–87) 60 (42–79)
Females (n, %) 30 (100 %) 30 (100 %)
AMA positivity (n, %) 28 (93 %) n.a.
Liver cirrhosis (n, %) 4 (13 %) n.a.
Total bilirubin (mg/dl) (n.v. <1.0) 0.64 ± 0.39 0.73 ± 0.18
Alkaline phosphatase (IU/l) (n.v. <279) 152.3 ± 207.3 168 ± 24
Alanine aminotransferase (U/l) (n.v. <50) 33 ± 26 32 ± 9
Albumin (g/dl) (n.v. >3.5) 4.33 ± 0.86 4.68 ± 0.03
Length of follow-up (months, range) 34 (14–56) n.a.
Therapy with UDCA (n, %) 28 (93 %) n.a.
Liver biopsy (n, %) 21 (72 %) n.a.
Mean values ± standard deviation unless otherwise stated
n.a. not applicable, n.v. normal value
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All reactions were run in duplicate. The relative mRNA
expression level of each gene was determined by normal-
izing its mRNA level to the internal control glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH).
Flow cytometry
Phenotypic analysis of CD4 T cells was assessed using
fluorochrome-conjugated monoclonal antibodies against
cell surface markers on a FACSCantoII (BD Biosciences,
San Diego, CA, USA) using FACSDiva™ software (BD
Biosciences, San Diego, CA, USA). Monoclonal anti-
bodies against human CD3, CD4, CD45RA, CD45RO,
and CD183 (CXCR3) were purchased from BioLegend
(San Diego, CA, USA). Frozen cells were thawed and
prepared for flow cytometry as described [44]. Cells were
stained for 15 min at room temperature with Aqua via-
bility dye (Life Technologies). Optimal concentrations of
the mAbs were used throughout, and all assays included
positive and negative controls.
Statistical methods
NimbleScan software v2.5 (Roche NimbleGen, Madison,
WI, USA) was utilized for DNA methylation data analysis
using a threshold p value of 0.05 equivalent to 1.31 based
on the Gaussian distribution of data. Second, exclusive
elements corresponding to specific microarray probes
were identified using a one-sided Kolmogorov-Smirnov
(KS) test in affected and healthy subjects; peaks found only
in either group were selected for further analysis. Peaks
within 500 bp of each other are merged. If several adjacent
probes rise significantly above a set threshold, the region
is assigned to an enrichment peak (EP). NimbleScan
detects peaks by searching for at least two probes above a
p value minimum cutoff (−log10) of 2. Third, elements of
interest were inserted into the UCSC Genome Browser to
identify corresponding genes. The filter condition of differ-
ent methylated regions was set to be no less than six EPs
in one group and not more than three EPs in the other
group. Based on GO analysis and potential involvement in
the pathogenesis of PBC, four genes were selected for val-
idation using isolated CD4+, CD8+, and CD14+ cells from
20 additional patients with PBC and 20 additional normal
controls. For RT-qPCR, the data were analyzed with Delta
Delta Ct using global normalization. Statistical differences
between groups were identified using an unpaired t test
taking into account transcripts with p value <0.05.
Additional file
Additional file 1: Supplementary table.
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